Drug-target analyses suggested that modulation of the complement and coagulation cascades may benefit pneumonia patients with comorbid LC or COPD, highlighting <i>CFB</i>, <i>SERPINA1</i>, and <i>SERPING1</i> as key candidates and pointing to monocyte-centered pathways as promising therapeutic directions. Here, CFB is linked to laryngotracheoesophageal cleft.